Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid Tumors
Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus with the goal of addressing solid tumors.
Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev
Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd.
EMA grants positive opinion for orphan drug status for ovarian cancer oncolytic vaccine
PsiOxus Therapeutics Ltd. (PsiOxus), an Oxford, UK based biotechnology company developing innovative new treatments for cancer, has been granted a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) for an orphan medicinal product designation of its oncolytic vaccine, enadenotucirev (previously known as ColoAd1) for the treatment of platinum-resistant epithelial ovarian cancer.
PsiOxus Initiates Combination Study of Merck’s Keytruda with Oncolytic Virus Enadenotucirev
PsiOxus Therapeutics Ltd. (PsiOxus), the immuno- oncology company, has initiated a study to assess the safety and efficacy of a therapy combining Merck’s Keytruda® (pembrolizumab) and PsiOxus’ lead product, enadenotucirev, to treat patients with carcinomas.
PsiOxus Therapeutics Announce Executive Team Reorganization with Two New C Level Appointments in the US
PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Dr Charles “Charlie” Morris as Chief Development Officer and Karen LaRochelle as Chief Business Officer, both of whom will be based in the United States.
PsiOxus Therapeutics Announce Two New Board Appointments: Strengthens US Presence
PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as part of an ongoing drive to expand in the US.
PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer.
PsiOxus Therapeutics, Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started a clinical trial with NG-641, a four transgene tumor-microenvironment modifying cancer gene therapy.
PsiOxus Therapeutics Announces First-in-Human Dosing of their Second Gene Therapy Cancer Treatment.
PsiOxus Therapeutics, Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started dosing NG-350A, an antibody based cancer gene therapy, to cancer patients.
PsiOxus Therapeutics Appoints Dr Paolo Paoletti as Chairman of the Board
PsiOxus Therapeutics Ltd. (“PsiOxus”), the immuno-oncology company, has appointed Dr Paolo Paoletti, MD as Chairman of the Board.
PsiOxus Therapeutics Expands operations in both Oxford, UK and Philadelphia, USA
PsiOxus Therapeutics, Ltd. (PsiOxus), the cancer therapeutics company, today announced expansion of operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK.
PsiOxus Therapeutics Initiates Combination of Paclitaxel with Oncolytic Virus Enadenotucirev in Ovarian Cancer Study
PsiOxus Therapeutics Ltd. (PsiOxus), the immunooncology company, today announced the first treatment of a patient to combine paclitaxel with the oncolytic virotherapy enadenotucirev in the OCTAVE (Ovarian Cancer Treated with Adeno Vaccine Enadenotucirev) study.